NZ534836A - Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction - Google Patents

Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction

Info

Publication number
NZ534836A
NZ534836A NZ534836A NZ53483600A NZ534836A NZ 534836 A NZ534836 A NZ 534836A NZ 534836 A NZ534836 A NZ 534836A NZ 53483600 A NZ53483600 A NZ 53483600A NZ 534836 A NZ534836 A NZ 534836A
Authority
NZ
New Zealand
Prior art keywords
antagonist
endometrial tissue
treatment
therapeutic management
contraceptive
Prior art date
Application number
NZ534836A
Other languages
English (en)
Inventor
Jurgen Engel
Hilde Riethmuller-Winzen
Ricardo Felberbaum
Klaus Diedrich
Wolfgang Kupker
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NZ534836A publication Critical patent/NZ534836A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
NZ534836A 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction NZ534836A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23

Publications (1)

Publication Number Publication Date
NZ534836A true NZ534836A (en) 2007-07-27

Family

ID=22555601

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ534836A NZ534836A (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction

Country Status (22)

Country Link
EP (1) EP1214086A2 (hu)
JP (2) JP2003509467A (hu)
KR (1) KR100772852B1 (hu)
CN (2) CN1376070A (hu)
AU (1) AU769482B2 (hu)
BG (1) BG66128B1 (hu)
BR (1) BR0014198A (hu)
CA (1) CA2383510A1 (hu)
HK (1) HK1049117A1 (hu)
HU (1) HUP0202741A3 (hu)
IL (1) IL148185A0 (hu)
MX (1) MXPA02002436A (hu)
NO (1) NO331198B1 (hu)
NZ (1) NZ534836A (hu)
PL (1) PL201898B1 (hu)
RU (1) RU2255759C2 (hu)
SK (1) SK3752002A3 (hu)
TR (1) TR200200738T2 (hu)
TW (1) TWI267373B (hu)
UA (1) UA73956C2 (hu)
WO (1) WO2001021194A2 (hu)
ZA (1) ZA200201374B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
DK2252627T3 (en) 2008-01-24 2017-08-14 Esperance Pharmaceuticals MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME.
CA2750582A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
CA2889475A1 (en) 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
CA3097340A1 (en) 2018-04-19 2019-10-24 Abbvie Inc. Methods of treating heavy menstrual bleeding
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (sv) * 1993-05-07 1993-05-07 Per-Christer Oden Composition for the treatment of impaired hair growth
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
ES2145286T3 (es) * 1994-07-22 2000-07-01 Hampton Roads Medical College Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica.
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
WO1998009645A1 (fr) * 1996-09-04 1998-03-12 Dott Research Laboratory Compositions medicamenteuses contenant des peptides, destinees a l'administration orale
WO1998055470A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung

Also Published As

Publication number Publication date
CA2383510A1 (en) 2001-03-29
WO2001021194A3 (en) 2002-03-14
NO20021430L (no) 2002-05-07
EP1214086A2 (en) 2002-06-19
PL353244A1 (en) 2003-11-03
AU7779200A (en) 2001-04-24
JP2003509467A (ja) 2003-03-11
MXPA02002436A (es) 2003-02-12
NO20021430D0 (no) 2002-03-21
PL201898B1 (pl) 2009-05-29
RU2255759C2 (ru) 2005-07-10
BG106584A (bg) 2003-02-28
WO2001021194A2 (en) 2001-03-29
KR100772852B1 (ko) 2007-11-02
HK1049117A1 (zh) 2003-05-02
AU769482B2 (en) 2004-01-29
BR0014198A (pt) 2002-05-21
NO331198B1 (no) 2011-10-31
TR200200738T2 (tr) 2002-08-21
IL148185A0 (en) 2002-09-12
UA73956C2 (en) 2005-10-17
CN1376070A (zh) 2002-10-23
CN101045155A (zh) 2007-10-03
BG66128B1 (bg) 2011-06-30
SK3752002A3 (en) 2003-06-03
HUP0202741A2 (hu) 2003-01-28
HUP0202741A3 (en) 2003-12-29
TWI267373B (en) 2006-12-01
ZA200201374B (en) 2002-10-30
JP2012051920A (ja) 2012-03-15
KR20020035879A (ko) 2002-05-15

Similar Documents

Publication Publication Date Title
JP3130048B2 (ja) エストロゲン依存症の治療
ES2281551T3 (es) Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
Erkkola et al. Role of progestins in contraception
JP2012051920A (ja) 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用
JP2013523683A (ja) アロマターゼ阻害剤およびゲスターゲンを放出する、子宮内膜症を処置するための非経口用剤形
TW577735B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
KR20100068287A (ko) 폐경기 전 여성의 에스트로겐 의존성 질환의 치료
US7666836B2 (en) Method for the therapeutic management of endometriosis
Bedaiwy et al. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists
JP2012077020A (ja) ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
Bergqvist Current drug therapy recommendations for the treatment of endometriosis
BG106442A (bg) Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания
BG63363B1 (bg) Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания
JP3925688B2 (ja) ＧｎＲＨａ治療中および／またはＧｎＲＨａ治療後の副作用を治療するための製薬学的調剤
BR112020021565A2 (pt) Composição para tratamento de uma ou mais doenças relacionadas com estrogênio
Wong et al. Exogenous Hormone-Induced Endometrial Changes
Patel Response of the Uterus to Medication: Hysteroscopic Implications
Patel 6 Hysteroscopic Implications

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed